Control of Osteoclast Activity and Bone Loss by IKK Subunits: New Targets for Therapy

Maria Grazia Ruocco; Michael Karin

doi:10.1007/978-0-387-72009-8_16

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2005

IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss

Maria Grazia Ruocco, Shin Maeda, Jin Mo Park, Toby Lawrence, Li‐Chung Hsu, Yixue Cao, Georg Schett, Erwin F. Wagner, Michael Karin

Chapter in a book1999

New Targets for Future Asthma Therapy

Peter J Barnes

Article2014

New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy

Spiros Vlahopoulos, Elena Critselis, Ioannis F. Voutsas, Sonia A. Perez, Maria Moschovi, Constantin N. Baxevanis, George Chrousos

Article2010

Anti–Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation

Lieve Coenegrachts, Christa Maes, Sophie Torrekens, Riet Van Looveren, Massimiliano Mazzone, Theresa A. Guise, Roger Bouillon, Jean-Marie Stassen, Peter Carmeliet, Geert Carmeliet

Article2012

The Transcription Factor Jdp2 Controls Bone Homeostasis and Antibacterial Immunity by Regulating Osteoclast and Neutrophil Differentiation

Kenta Maruyama, Masahiro Fukasaka, Alexis Vandenbon, Tatsuya Saitoh, Takumi Kawasaki, Takeshi Kondo, Kazunari K. Yokoyama, Hiroyasu Kidoya, Nobuyuki Takakura, Daron M Standley, Osamu Takeuchi, Akira Shizuo

Immunity